Literature DB >> 3342762

The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man.

G Baumann1, K Amburn, M A Shaw.   

Abstract

The recent discovery of a specific binding protein for human GH (hGH) in human plasma suggests that hGH circulates in part as a complex in association with the binding protein(s). However, the magnitude of the complexed fraction prevailing under physiological conditions is unknown because of 1) dissociation of the complex during analysis and 2) potential differences in the binding characteristics of radiolabeled and native hGH. We conducted experiments designed to minimize dissociation during analysis (gel filtration in prelabeled columns, frontal analysis, and batch molecular sieving) with both native and radioiodinated hGH. All three methods yielded similar estimates for the complexed fraction. In normal plasma the bound fraction for 22 K hGH averaged 50.1% (range, 39-59%), that for 20 K hGH averaged 28.5% (range, 26-31%). Above a hGH level of about 20 ng/ml the bound fraction declines in concentration-dependent manner due to saturation of the binding protein. We conclude that a substantial part of circulating hGH is complexed with carrier proteins. This concept has important implications for the metabolism, distribution, and biological activity of hGH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3342762     DOI: 10.1210/endo-122-3-976

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

Review 1.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

Review 2.  Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors:  Iftekhar Mahmood; Martin D Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  The relevance of pharmacokinetics in the development of biotechnology products.

Authors:  S Toon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

4.  Plasma clearance of heterogeneous growth hormone components in the rat: effects of diabetes and starvation.

Authors:  T Jolin; C González
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

Review 5.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

6.  Urinary growth hormone excretion rates in normal and acromegalic man: a critical appraisal of its potential clinical utility.

Authors:  L M Winer; M A Shaw; G Baumann
Journal:  J Endocrinol Invest       Date:  1989 Jul-Aug       Impact factor: 4.256

7.  Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.

Authors:  Zufei Zhang; Muhammad Farooq; Bhagwat Prasad; Sue Grepper; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2015-03-23       Impact factor: 3.922

8.  Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

Authors:  J Mordenti; S A Chen; J A Moore; B L Ferraiolo; J D Green
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

9.  Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications.

Authors:  J D Veldhuis; M L Johnson; L M Faunt; M Mercado; G Baumann
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

Review 10.  Growth hormone binding protein and free growth hormone in chronic renal failure.

Authors:  G Baumann
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.